[10]-gingerol induces apoptosis and inhibits metastatic dissemination of triple negative breast cancer in vivo

Martin, Ana Carolina B.M., Fuzer, Angelina M., Becceneri, Amanda B., da Silva, James Almada, Tomasin, Rebeka, Denoyer, Delphine, Kim, Soo-Hyun, McIntyre, Katherine A., Pearson, Helen B. ORCID: https://orcid.org/0000-0002-3284-0843, Yeo, Belinda, Nagpal, Aadya, Ling, Xiawei, Selistre-de-Araújo, Heloisa S., Vieira, Paulo Cézar, Cominetti, Marcia R. and Pouliot, Normand 2017. [10]-gingerol induces apoptosis and inhibits metastatic dissemination of triple negative breast cancer in vivo. Oncotarget 8 (42) , pp. 72260-72271. 10.18632/oncotarget.20139

PDF - Published Version Available under License Creative Commons Attribution. Download (15MB)

Abstract

There is increasing interest in the use of non-toxic natural products for the treatment of various pathologies, including cancer. In particular, biologically active constituents of the ginger oleoresin (Zingiber officinale Roscoe) have been shown to mediate anti-tumour activity and to contribute to the anti-inflammatory, antioxidant, antimicrobial, and antiemetic properties of ginger. Here we report on the inhibitory properties of [10]-gingerol against metastatic triple negative breast cancer (TNBC) in vitro and in vivo. We show that [10]-gingerol concentration-dependently induces apoptotic death in mouse and human TNBC cell lines in vitro. In addition, [10]-gingerol is well tolerated in vivo, induces a marked increase in caspase-3 activation and inhibits orthotopic tumour growth in a syngeneic mouse model of spontaneous breast cancer metastasis. Importantly, using both spontaneous and experimental metastasis assays, we show for the first time that [10]-gingerol significantly inhibits metastasis to multiple organs including lung, bone and brain. Remarkably, inhibition of brain metastasis was observed even when treatment was initiated after surgical removal of the primary tumour. Taken together, these results indicate that [10]-gingerol may be a safe and useful complementary therapy for the treatment of metastatic breast cancer and warrant further investigation of its efficacy, either alone or in combination with standard systemic therapies, in pre-clinical models of metastatic breast cancer and in patients.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Biosciences European Cancer Stem Cell Research Institute (ECSCRI)
Publisher:	Impact Journals
ISSN:	1949-2553
Date of First Compliant Deposit:	8 May 2019
Date of Acceptance:	29 July 2017
Last Modified:	29 Jun 2023 10:07
URI:	https://orca.cardiff.ac.uk/id/eprint/122187

Citation Data

Cited 55 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item